Hematology-Oncology Associates of the Quad-Cities, PC
Breast Cancer Trials
Accelerated Community Oncology Research Network, Inc. (ACORN) Protocol ALSSMBC0804: Phase I/II Trial of Dasatinib plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab- Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
NCCTG 0733: Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in HER2 + Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
CALGB 40503: Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer
CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab- Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
NCCTG 0733: Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in HER2 + Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
CALGB 40503: Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer
